– DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with a mixed lineage leukemia...

– DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia – MARLBOROUGH, Mass., June 14, 2024 /PRNewswire

–Supplemental New Drug Application (sNDA) submission based on Phase 3 study of vibegron 75mg (GEMTESA) demonstrating statistically significant reductions in daily micturition and urgency episodes–

–Data includes results from Phase 3 study of vibegron 75mg (GEMTESA) in men living with overactive bladder receiving pharmacological treatment for benign prostatic hyperplasia– MARLBOROUGH, Mass.,

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President, and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) and its U.S.-based subsidiary...